Implications of ACMG Guidelines to Identify High-risk Acute Lymphoblastic Leukemia Patients with Hereditary Cancer Susceptibility Syndromes (HCSS) in a Highly Consanguineous Population

Overview

Journal BMC Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2021 Jun 17

PMID 34134655

Authors

Sara Aslam

Shabana

Mehboob Ahmed

Affiliations

Soon will be listed here.

Abstract

Background: Hereditary cancer susceptibility syndrome (HCSS) contributes to the cancer predisposition at an early age, therefore, identification of HCSS has found to be crucial for surveillance, managing therapeutic interventions and refer the patients and their families for genetic counselling. The study aimed to identify ALL patients who meet the American College of Medical Genetics (ACMG) criteria and refer them for the genetic testing for HCSS as hereditary leukemia and hematologic malignancy syndrome, and to elucidate the significance of high consanguinity with the prevalence of inherited leukemia in Pakistani population.

Methods: A total of 300 acute lymphoblastic leukemia patients were recruited from the Children's Hospital, Lahore, Pakistan from December 2018 to September 2019. A structured self-reporting questionnaire based on family and medical history of the disease was utilized for the data collection.

Results: In our cohort, 60.40% of ALL patients were identified to meet ACMG criteria. Among them, a large number of patients (40.65%) solely fulfil the criteria due to the presence of parental consanguinity. However, parental consanguinity showed protective impact on the onset at early age of disease [OD = 0.44 (0.25-0.77), p-value = 0.00] while, a family history of cancer increased the risk of cardiotoxicity [OD = 2.46 (1.15-5.24), p-value = 0.02]. Parental consanguinity shows no significant impact on the family history of cancer and the number of relatives with cancer.

Conclusions: More than 50% of the ALL patients were considered the strong candidates' for genetic testing of HCSS in the Pakistani population, and parental consanguinity was the leading criteria fulfilled by the individuals when assessed through ACMG guidelines. Our study suggests revisiting ACMG guidelines, especially for the criterion of parental consanguinity, and formulating the score based criteria based on; genetic research, the toxicology profile, physical features, personal and family history of cancer for the identification of patients for the genetic testing.

References

Bener A, El Ayoubi H, Chouchane L, Ali A, Al-Kubaisi A, Al-Sulaiti H . Impact of consanguinity on cancer in a highly endogamous population. Asian Pac J Cancer Prev. 2009; 10(1):35-40. View

Elalaoui S, Cherkaoui Jaouad I, Laarabi F, Elgueddari B . Low level of consanguinity in moroccan families at high risk of breast cancer. Asian Pac J Cancer Prev. 2013; 14(2):723-6. DOI: 10.7314/apjcp.2013.14.2.723. View

Sinnett D, Krajinovic M, Labuda D . Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2000; 38(5-6):447-62. DOI: 10.3109/10428190009059264. View

Yang X, Li G, Yang T, Guan M, An N, Yang F . Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity. Oxid Med Cell Longev. 2020; 2020:4894625. PMC: 7578723. DOI: 10.1155/2020/4894625. View

Ripperger T, Beger C, Rahner N, Sykora K, Bockmeyer C, Lehmann U . Constitutional mismatch repair deficiency and childhood leukemia/lymphoma--report on a novel biallelic MSH6 mutation. Haematologica. 2009; 95(5):841-4. PMC: 2864393. DOI: 10.3324/haematol.2009.015503. View

Knapke S, Nagarajan R, Correll J, Kent D, Burns K . Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr Blood Cancer. 2011; 58(1):85-9. DOI: 10.1002/pbc.23283. View

Baris H, Barnes-Kedar I, Toledano H, Halpern M, Hershkovitz D, Lossos A . Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity. Pediatr Blood Cancer. 2015; 63(3):418-27. DOI: 10.1002/pbc.25818. View

Giri V, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty S . Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precis Oncol. 2021; 1. PMC: 8210976. DOI: 10.1200/PO.16.00039. View

Jastaniah W . Successful treatment of mature B-cell lymphoma with rituximab-based chemotherapy in a patient with Bloom syndrome. Pediatr Blood Cancer. 2016; 64(7). DOI: 10.1002/pbc.26385. View

10.

Jastaniah W, Aljefri A, Ayas M, AlHarbi M, Alkhayat N, Al-Anzi F . Prevalence of hereditary cancer susceptibility syndromes in children with cancer in a highly consanguineous population. Cancer Epidemiol. 2018; 55:88-95. DOI: 10.1016/j.canep.2018.05.006. View

11.

Bashford M, Kohlman W, Everett J, Parrott A, Pollin T . Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2019; 21(12):2844. DOI: 10.1038/s41436-019-0586-y. View

12.

Afzal M . Childhood Cancer in Pakistan. Iran J Public Health. 2020; 49(8):1579. PMC: 7554396. DOI: 10.18502/ijph.v49i8.3908. View

13.

Soegaard M, Jensen A, Frederiksen K, Hogdall E, Hogdall C, Blaakaer J . Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control. 2008; 19(5):469-79. DOI: 10.1007/s10552-007-9108-3. View

14.

Ozanne E, OConnell A, Bouzan C, Bosinoff P, Rourke T, Dowd D . Bias in the reporting of family history: implications for clinical care. J Genet Couns. 2012; 21(4):547-56. DOI: 10.1007/s10897-011-9470-x. View

15.

Darr A, Small N, Ahmad W, Atkin K, Corry P, Modell B . Addressing key issues in the consanguinity-related risk of autosomal recessive disorders in consanguineous communities: lessons from a qualitative study of British Pakistanis. J Community Genet. 2015; 7(1):65-79. PMC: 4715815. DOI: 10.1007/s12687-015-0252-2. View

16.

Magdy T, Burmeister B, Burridge P . Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. Pharmacol Ther. 2016; 168:113-125. PMC: 5140687. DOI: 10.1016/j.pharmthera.2016.09.009. View

17.

Caswell-Jin J, Gupta T, Hall E, Petrovchich I, Mills M, Kingham K . Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Med. 2017; 20(2):234-239. DOI: 10.1038/gim.2017.96. View

18.

Rabin K, Poplack D . Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park). 2011; 25(4):328-35. View

19.

Zhang J, Walsh M, Wu G, Edmonson M, Gruber T, Easton J . Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015; 373(24):2336-2346. PMC: 4734119. DOI: 10.1056/NEJMoa1508054. View

20.

Lu K, Wood M, Daniels M, Burke C, Ford J, Kauff N . American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol. 2014; 32(8):833-40. PMC: 3940540. DOI: 10.1200/JCO.2013.50.9257. View